2. Academic Validation
  3. Transforming growth factor-β receptor I kinase plays a crucial role in oligodendrocyte regeneration after demyelination

Transforming growth factor-β receptor I kinase plays a crucial role in oligodendrocyte regeneration after demyelination

  • Biomed Pharmacother. 2025 Jun:187:118094. doi: 10.1016/j.biopha.2025.118094.
Yunkyoung Lee 1,  Inyoung Jung 2,  Dong-Won Lee 1,  Yongbo Seo 3,  Suhyun Kim 4,  Hae-Chul Park 5
Affiliations

Affiliations

  • 1 Core Research and Development Center, Korea University Ansan Hospital, Ansan, Gyeonggi-do 15588, Republic of Korea; Zebrafish Translational Medical Research Center, College of Medicine, Korea University, Ansan, Gyeonggi-do 15588, Republic of Korea.
  • 2 Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Erling Skalgssons gate 1, Trondheim 7030, Norway.
  • 3 Zebrafish Translational Medical Research Center, College of Medicine, Korea University, Ansan, Gyeonggi-do 15588, Republic of Korea.
  • 4 Zebrafish Translational Medical Research Center, College of Medicine, Korea University, Ansan, Gyeonggi-do 15588, Republic of Korea; Department of Convergence Medicine, Korea University College of Medicine, Seoul 04763, Republic of Korea.
  • 5 Core Research and Development Center, Korea University Ansan Hospital, Ansan, Gyeonggi-do 15588, Republic of Korea; Zebrafish Translational Medical Research Center, College of Medicine, Korea University, Ansan, Gyeonggi-do 15588, Republic of Korea; Department of Convergence Medicine, Korea University College of Medicine, Seoul 04763, Republic of Korea. Electronic address: dieslunae@korea.ac.kr.
PMID: 40315672 DOI: 10.1016/j.biopha.2025.118094
Abstract

Multiple sclerosis (MS) is an autoimmune disease characterized by the loss of oligodendrocytes (OLs) and axon demyelination in the central nervous system. Most therapeutic agents focus on regulating the immune response by suppressing autoimmune reactions. Therefore, developing therapeutic agents that promote remyelination by OLs at disease sites that have already undergone demyelination is necessary. In this study, we generated a new transgenic zebrafish with high efficiency for OL ablation and established a high-throughput screening (HTS)-based platform to identify therapeutic candidates that promote remyelination. Next, we screened a library of kinase inhibitors and identified one candidate, a transforming growth factor-β receptor I (TGF-βRI) kinase inhibitor. Treatment with this kinase inhibitor rapidly recruited microglia to induce clearance of myelin debris, early after OL removal. It also increased the proliferation of OL progenitor cells in demyelinating zebrafish larvae, resulting in restored OL numbers and reduced locomotor activity. Based on these results, we expect our HTS-based platform, along with our newly developed zebrafish model, to be very useful for identifying therapeutic agents that promote remyelination. Furthermore, since the candidate TGF-βRI kinase inhibitor identified in this study restored the phenotype following demyelination, we suggest that TGF-βRI kinase may potentially be a therapeutic target for the treatment of demyelinating diseases.

Keywords

Demyelinating diseases; High-throughput screening; Multiple sclerosis; Oligodendrocyte; TGF-β receptor I kinase; Zebrafish.

Figures
Products
Inhibitors & Agonists
Other Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z